Nancy Rogacki

Summary

Affiliation: Sanofi-Aventis Deutschland GmbH

Publications

  1. ncbi The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition
    Nancy Rogacki
    Sanofi Aventis, CNS Department, 1041 Route 202 206, Bridgewater, NJ 08807, USA
    Pharmacol Biochem Behav 98:405-11. 2011
  2. ncbi AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
    Mark D Black
    Sanofi Aventis, Bridgewater, NJ 08807, USA
    Psychopharmacology (Berl) 215:149-63. 2011
  3. ncbi Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
    Denis Boulay
    Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
    Pharmacol Biochem Behav 91:47-58. 2008

Detail Information

Publications3

  1. ncbi The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition
    Nancy Rogacki
    Sanofi Aventis, CNS Department, 1041 Route 202 206, Bridgewater, NJ 08807, USA
    Pharmacol Biochem Behav 98:405-11. 2011
    ..In contrast, the benzodiazepine, diazepam (DZM), produced cognitive impairments. NK2 receptor antagonists like saredutant may therefore yield beneficial effects for mood disorders without the adverse effects of current treatments...
  2. ncbi AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
    Mark D Black
    Sanofi Aventis, Bridgewater, NJ 08807, USA
    Psychopharmacology (Berl) 215:149-63. 2011
    ..The psychotomimetic effects of cannabis are believed to be mediated via cannabinoid CB1 receptors. Furthermore, studies have implicated CB1 receptors in the pathophysiology of schizophrenia...
  3. ncbi Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
    Denis Boulay
    Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
    Pharmacol Biochem Behav 91:47-58. 2008
    ..o.), respectively. These findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states...